Merck & Co. will apply the somatic genomics platform Quotient Therapeutics to discover novel drug targets in inflammatory bowel disease (IBD), through a collaboration that could generate up to $2.2 ...

High-sensitivity sequencing of recurrent, cell-type–specific variants aims to strengthen causal inference versus germline ...